These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18929703)

  • 1. Pleiotropic effect of lovastatin, with and without cholestyramine, in the post coronary artery bypass graft (Post CABG) trial.
    Domanski M; Tian X; Fleg J; Coady S; Gosen C; Kirby R; Sachdev V; Knatterud G; Braunwald E
    Am J Cardiol; 2008 Oct; 102(8):1023-7. PubMed ID: 18929703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.
    Post Coronary Artery Bypass Graft Trial Investigators
    N Engl J Med; 1997 Jan; 336(3):153-62. PubMed ID: 8992351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial.
    Alaupovic P; Fesmire JD; Hunnighake D; Domanski M; Forman S; Knatterud GL; Forrester J; Herd JA; Hoogwerf B; Campeau L; Gobel FL
    Atherosclerosis; 1999 Oct; 146(2):369-79. PubMed ID: 10532693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators.
    Campeau L; Hunninghake DB; Knatterud GL; White CW; Domanski M; Forman SA; Forrester JS; Geller NL; Gobel FL; Herd JA; Hoogwerf BJ; Rosenberg Y
    Circulation; 1999 Jun; 99(25):3241-7. PubMed ID: 10385497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy.
    Hunninghake DB
    Am J Med; 1998 Feb; 104(2A):9S-13S. PubMed ID: 9550501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between obesity and atherosclerotic progression and prognosis among patients with coronary artery bypass grafts the effect of aggressive statin therapy.
    Wee CC; Girotra S; Weinstein AR; Mittleman MA; Mukamal KJ
    J Am Coll Cardiol; 2008 Aug; 52(8):620-5. PubMed ID: 18702964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of cholesterol lowering and cardiovascular risk factors on the progression of aortoiliac arteriosclerosis: a quantitative cineangiography study.
    Campeau L; Lespérance J; Bilodeau L; Fortier A; Guertin MC; Knatterud GL
    Angiology; 2005; 56(2):191-9. PubMed ID: 15793608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial.
    White CW; Gobel FL; Campeau L; Knatterud GL; Forman SA; Forrester JS; Geller NL; Herd JA; Hickey A; Hoogwerf BJ; Hunninghake DB; Rosenberg Y; Terrin ML;
    Circulation; 2001 Nov; 104(22):2660-5. PubMed ID: 11723015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is aggressive cholesterol control justified? Review of the post-coronary artery bypass graft trial.
    Hunninghake DB
    Am J Cardiol; 1998 Nov; 82(10B):45T-48T. PubMed ID: 9860374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of aorto-saphenous vein bypass narrowing late after coronary artery bypass grafting.
    Rodés-Cabau J; Facta A; Larose E; DeLarochellière R; Déry JP; Nguyen CM; Roy L; Proulx G; Gleeton O; Barbeau G; Noël B; Rouleau J; Boudreault JR; Bertrand OF
    Am J Cardiol; 2007 Aug; 100(4):640-5. PubMed ID: 17697821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin therapy and saphenous vein graft disease after coronary bypass surgery: analysis from the CASCADE randomized trial.
    Kulik A; Voisine P; Mathieu P; Masters RG; Mesana TG; Le May MR; Ruel M
    Ann Thorac Surg; 2011 Oct; 92(4):1284-90; discussion 1290-1. PubMed ID: 21958773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive versus moderate statin therapy and early graft occlusion after coronary bypass surgery: The Aggressive Cholesterol Therapy to Inhibit Vein Graft Events randomized clinical trial.
    Kulik A; Abreu AM; Boronat V; Ruel M
    J Thorac Cardiovasc Surg; 2019 Jan; 157(1):151-161.e1. PubMed ID: 30122341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of aggressive lipid controlling therapy for preventing saphenous vein graft disease.
    Hata M; Takayama T; Sezai A; Yoshitake I; Hirayama A; Minami K
    Ann Thorac Surg; 2009 Nov; 88(5):1440-4. PubMed ID: 19853088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors for atherosclerosis progression in saphenous vein grafts: the postcoronary artery bypass graft (Post-CABG) trial. Post-CABG Trial Investigators.
    Domanski MJ; Borkowf CB; Campeau L; Knatterud GL; White C; Hoogwerf B; Rosenberg Y; Geller NL
    J Am Coll Cardiol; 2000 Nov; 36(6):1877-83. PubMed ID: 11092659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin initiation following coronary artery bypass grafting: outcome of a hospital discharge protocol.
    Khanderia U; Townsend KA; Eagle K; Prager R
    Chest; 2005 Feb; 127(2):455-63. PubMed ID: 15705982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials.
    Kang S; Liu Y; Liu XB
    Clin Ther; 2013 Aug; 35(8):1125-36. PubMed ID: 23932462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial (CLAPT).
    Kleemann A; Eckert S; von Eckardstein A; Lepper W; Schernikau U; Gleichmann U; Hanrath P; Fleck E; Neiss A; Kerber S; Assmann G; Breithardt G;
    Eur Heart J; 1999 Oct; 20(19):1393-406. PubMed ID: 10487800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Multicenter comparative study on safety, tolerance, and effectiveness of lovastatin combined or not with cholestyramine, and gemfibrozil combined or not with cholestyramine in the treatment of primary hypercholesterolemia].
    Jover E; Aranda JL; Nogués X; del Palacio A; Rubiés-Prat J
    Med Clin (Barc); 1996 May; 106(20):776-9. PubMed ID: 8801396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive versus moderate atorvastatin therapy and one-year graft patency after CABG: Rationale and design of the ACTIVE (Aggressive Cholesterol Therapy to Inhibit Vein Graft Events) randomized controlled trial (NCT01528709).
    Kulik A; Abreu AM; Boronat V; Ruel M
    Contemp Clin Trials; 2017 Aug; 59():98-104. PubMed ID: 28611006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.